Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of infliximab treatment on immune cells in blood of patients with spondyloarthritis
2008-001853-17Phase 4Completed
- Sponsor
- Ghent University Hospital
- Start
- May 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in spondyloarthritis (SpA), sponsored by Ghent University Hospital. Primary endpoints: Expression of surface markers on PBMC and Expression of cytokines by PBMC. Started May 2008; status: completed.
02
Drugs
infliximab
03
Conditions
spondyloarthritis (SpA)
Beyond the preview
Go deeper on 2008-001853-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001853-17.